Prosecution Insights
Last updated: October 21, 2026
Application No. 18/025,638

5-SUBSTITUTED INDOLE 3-AMIDE DERIVATIVES, PREPARATION METHOD AND USE THEREOF

Final Rejection §112
Filed
Mar 09, 2023
Priority
Sep 09, 2020 — CN 202010943478.3 +2 more
Examiner
SHOWALTER, ALEXANDER KEITH
Art Unit
1629
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Origiant Pharmaceutical Co. Ltd.
OA Round
2 (Final)
55%
Grant Probability
Moderate
3-4
OA Rounds
0m
Est. Remaining
83%
With Interview

Examiner Intelligence

Grants 55% of resolved cases
55%
Career Allowance Rate
51 granted / 92 resolved
-4.6% vs TC avg
Strong +27% interview lift
Without
With
+27.3%
Interview Lift
resolved cases with interview
Typical timeline
3y 7m
Avg Prosecution
25 currently pending
Career history
128
Total Applications
across all art units

Statute-Specific Performance

§101
3.5%
-36.5% vs TC avg
§103
34.9%
-5.1% vs TC avg
§102
14.8%
-25.2% vs TC avg
§112
31.4%
-8.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 92 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Priority The present Application, filed March 9, 2023, is a national stage entry under 35 U.S.C. § 371 of International Patent Application No. PCT/CN2021/116256, filed September 2, 2021, which claims priority to Chinese Patent Application Nos. CN202110426935.6 and CN202010943478.3, filed April 20, 2021 and September 9, 2020, respectively. Status of the Claims In the amendment filed August 8, 2026, claims claim 12 is canceled and claims 1-2, 11, 18, and 25 are amended. Claims 22-23 were previously canceled. Claims 1-11 and 13-21 and 24-25 are currently pending with claims 3-8, 13, 16-17, 19-21, and 24 being withdrawn. Previous Rejections and/or Objections Any objections and/or rejections raised in the previous Office Action but not reiterated below are considered to have been withdrawn. Claim Rejections-- 35 USC § 112(d) – Necessitated by Amendment The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph: Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claim 18 is rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Claim 18 recites a number of compounds that are outside the scope of amended claim 1. For example, pg. 23, row 5, right column and rows 6-7 left column have a ring A that is thiazolopyridinyl group which is outside the scope of claim 1 as amended. The 250-plus species of claim 18 have not been thoroughly examined for compliance with the limitations of claim 1, and Applicant is encouraged to make a thorough examination. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Allowable Subject Matter Claims 1-2, 9-11, 13-15, and 25 are allowed. Conclusion THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to ALEXANDER K SHOWALTER whose telephone number is (571)270-0610. The examiner can normally be reached M-F 9:00 am to 5:00 pm, eastern time. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey S Lundgren can be reached on (571) 272-5541. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /ALEXANDER K. SHOWALTER/Examiner, Art Unit 1629 /JEFFREY S LUNDGREN/Supervisory Patent Examiner, Art Unit 1629
Read full office action

Prosecution Timeline

Mar 09, 2023
Application Filed
May 29, 2026
Non-Final Rejection mailed — §112
Aug 28, 2026
Response Filed
Oct 16, 2026
Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12747215
N2-ARYLMETHYL-4-HALOALKYL-PYRIDAZIN-3-ONE CFTR MODULATORS FOR THE TREATMENT OF CYSTIC FIBROSIS
4y 4m to grant Granted Sep 29, 2026
Patent 12741977
METHYLATION OF MCL-1 COMPOUNDS
4y 0m to grant Granted Sep 22, 2026
Patent 12741952
NOVEL COMPOUNDS
2y 10m to grant Granted Sep 22, 2026
Patent 12714711
SALTS OF NEUROCEUTICALS AND USES THEREOF
3y 9m to grant Granted Aug 25, 2026
Patent 12691109
A BIFUNCTIONAL AGGREGATION-INDUCED EMISSION LUMINOGEN FOR MONITORING AND KILLING OF MULTIDRUG-RESISTANT BACTERIA
5y 6m to grant Granted Jul 28, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
55%
Grant Probability
83%
With Interview (+27.3%)
3y 7m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 92 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month